Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 per ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc.

Future initial public offerings (IPOs) are being closely watched ... even if its GAAP net loss was only $0.2 million. Metsera, Inc. and Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have partnered ...